Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 7, 2008, Pages 2640-2645

  Shojaei, Farbod ^a   Singh, Mallika ^a   Thompson, Jennifer D ^a   Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

Author keywords

Myeloid cell; Prokineticin; Tumor; VEGF

Indexed keywords

ANTIBODY; CD11 ANTIGEN; MITOGENIC AGENT; CD11B ANTIGEN; GASTROINTESTINAL HORMONE; INSULIN; NEUROPEPTIDE; PROK2 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW; BONE MARROW CELL; CANCER GROWTH; CONTROLLED STUDY; DISEASE COURSE; HISTOLOGY; HYPERPLASIA; MOUSE; NEOPLASM; NEUTROPHIL; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; TRANSGENIC MOUSE; TUMOR GROWTH; XENOGRAFT; ANIMAL; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL CHEMOTAXIS; PANCREAS; PATHOLOGY; PROMOTER REGION; RAT; VASCULARIZATION;

MUS; MUS MUSCULUS; RATTUS;

ANIMALS; ANTIGENS, CD11B; BONE MARROW; DISEASE PROGRESSION; GASTROINTESTINAL HORMONES; GENE EXPRESSION REGULATION, NEOPLASTIC; INSULIN; MICE; MICE, TRANSGENIC; NEOPLASM STAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROPEPTIDES; NEUTROPHIL INFILTRATION; NEUTROPHILS; PANCREAS; PROMOTER REGIONS (GENETICS); RATS;

EID: 40649104348     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712185105     Document Type: Article

References (36)

1. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974.
2. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676.
3. Ferrara N, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
4. Ferrara N, Mass RD, Campa C, Kim R (2007) Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58:491-504.
5. Shojaei F, Ferrara N (2007) Antiangiogenic therapy for cancer: An update. Cancer J 13:345-348.
6. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867.
7. Shojaei F, et al. (2007) Bv8 regulates myeloid cell-dependent tumor angiogenesis Nature 450:825-831.
8. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
9. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812.
10. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D (2002) VEGF-A has a critical, nonredundant role in angiogenic swithing and pancreatic β cell carcinogenesis. Cancer Cell 1:193-202.
11. Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103:12493-12498.
12. Boisbouvier J, et al. (1998) A structural homologue of colipase in black mamba venom revealed by NMR floating disulphide bridge analysis. J Mol Biol 283:205-219.
13. Li M, Bullock CM, Knauer DJ, Ehlert FJ, Zhou QY (2001) Identification of two Prokineticin cDNAs: Recombinant proteins potently contract gestrointestinal smooth muscle. Mol Pharmacol 59:692-698.
14. LeCouter J, et al. (2001) Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412:877-884.
15. LeCouter J, et al. (2003) The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci USA 100:2685-2690.
16. Kaser A, Winklmayr M, Lepperdinger G, Kreil G (2003) The AVIT protein family. EMBO Rep 4:469-473.
17. Masuda Y, et al. (2002) Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G protein-coupled receptors. Biochem Biophys Res Commun 293:396-402.
18. Lin DC, et al. (2002) Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem 277:19276-19280.
19. Mollay C, et al. (1999) Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Eur J Pharmacol 374:189-196.
20. Joubert FJ, Strydom DJ (1980) Snake venom: The amino acid sequence of protein A from Dendroaspis polylepis polylepis (black mamba) venom. Hoppe-Seylers Zeitschrift Physiol Chem 361:1787-1794.
21. Schweitz H, Pacaud P, Diochot S, Moinier D, Ladzunski M (1999) MIT(1), a black mamba intestinal toxin with a new and highly potent activity on intestinal contraction. FEBS Lett 461:183-188.
22. Cheng MY, et al. (2002) Prokineticin 2 transmits the behavioral circadian rhythm of the suprachiasmatic nucleus. Nature 417:405-410.
23. Ng KL, et al. (2005) Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling. Science 308:1923-1927.
24. Matsumoto S, et al. (2006) Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. Proc Natl Acad Sci USA 103:4140-4145.
25. Dode C, et al. (2006) Kallmann syndrome: Mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2:e175.
26. LeCouter J, Lin R, Ferrara N (2002) Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 8:913-917.
27. Lin R, LeCouter J, Kowalski J, Ferrara N (2002) Characterization of EG-VEGF signaling in adrenal cortex capillary endothelial cells. J Biol Chem 277:8724-8729.
28. LeCouter J, Zlot C, Tejada M, Peale F, Ferrara N (2004) Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci USA 101:16813-16818.
29. Dorsch M, et al. (2005) PK1/EG-VEGF induces monocyte differentiation and activation. J Leukocyte Biol 78:426-434.
30. Yang L, et al. (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421.
31. De Palma M, et al. (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8:211-226.
32. Shojaei F, et al. (2007) Tumor refrectoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25:911-920.
33. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309.
34. LeCouter J, et al. (2003) Mouse endocrine-gland derived vascular endothelial growth factor: A distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. Endocrinology 144:2606-2616.
35. Bergers G, et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744.
36. Liang WC, et al. (2006) Cross-species VEGF-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281:951-961.